AI Portfolio Summary
In 2025 Q4, Deep Track Capital, LP maintained a portfolio of 73 distinct positions. The most significant new addition to the portfolio was SPDR SERIES TRUST, which now represents 21.74% of the total fund value. The fund also reduced its exposure to TERNS PHARMACEUTICAL by 89.7%.
Total Positions
73
Quarter
2025 Q4
Top Holding
XBI (21.7%)
Top 10 Concentration
60.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 73
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 21.74% | — |
#1
Prev: #—
|
9.5 | 10,000,000 | no change |
NEW
|
10,000,000 | $1,219,300,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 5.22% | 4.38% |
#2
5
Prev: #7
|
5.6 | 1,798,126 | 18.5% |
P
S
|
11,526,971 | $293,015,603 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GH
GUARDANT HEALTH...
|
Healthcare | 5.10% | 7.24% |
#3
2
Prev: #1
|
3.0 | -1,354,086 | -32.6% |
P
S
|
2,800,000 | $285,992,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 5.10% | 3.29% |
#4
7
Prev: #11
|
3.0 | -104,029 | -2.5% |
P
S
|
4,111,782 | $285,974,438 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 4.39% | 4.98% |
#5
1
Prev: #6
|
2.8 | 4,034 | 0.1% |
P
S
|
3,004,034 | $245,970,304 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DVAX
DYNAVAX TECHNOL...
|
Healthcare | 4.31% | 4.36% |
#6
2
Prev: #8
|
2.7 | no change | no change |
P
S
|
15,726,349 | $241,871,248 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 3.78% | 6.60% |
#7
4
Prev: #3
|
1.5 | -963,002 | -22.4% |
P
S
|
3,336,998 | $212,032,853 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 3.74% | 3.05% |
#8
6
Prev: #14
|
4.0 | 250,000 | 27.8% |
P
S
|
1,150,000 | $210,036,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 3.47% | 5.05% |
#9
4
Prev: #5
|
1.9 | -250,382 | -3.1% |
P
S
|
7,750,000 | $194,680,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 3.29% | 3.02% |
#10
5
Prev: #15
|
3.8 | 1,000,000 | 33.3% |
P
S
|
4,000,000 | $184,560,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 3.14% | 2.86% |
#11
5
Prev: #16
|
3.3 | 297,530 | 7.5% |
P
S
|
4,246,440 | $175,930,009 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 2.55% | — |
#12
Prev: #—
|
4.5 | 2,821,135 | no change |
NEW
|
2,821,135 | $142,862,276 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 2.44% | 0.04% |
#13
41
Prev: #54
|
4.0 | 2,275,144 | 9153.3% |
P
S
|
2,300,000 | $136,689,000 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 2.40% | 6.95% |
#14
12
Prev: #2
|
1.0 | -2,108,144 | -55.4% |
P
S
|
1,700,000 | $134,487,000 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 2.38% | 1.56% |
#15
6
Prev: #21
|
3.0 | 979,431 | 16.2% |
P
S
|
7,036,455 | $133,481,551 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.83% | 1.54% |
#16
6
Prev: #22
|
1.2 | 99,790 | 3.2% |
P
S
|
3,249,790 | $102,498,377 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 1.75% | 3.89% |
#17
8
Prev: #9
|
0.7 | -3,861,723 | -32.4% |
P
S
|
8,070,414 | $97,974,826 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GRAL
GRAIL INC
|
Healthcare | 1.56% | — |
#18
Prev: #—
|
4.1 | 1,022,797 | no change |
NEW
|
1,022,797 | $87,541,195 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 1.40% | 3.24% |
#19
7
Prev: #12
|
0.6 | -2,855,616 | -53.1% |
P
S
|
2,524,833 | $78,572,803 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 1.33% | 1.48% |
#20
4
Prev: #24
|
1.5 | no change | no change |
P
S
|
3,352,804 | $74,633,417 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMCR
IMMUNOCORE HLDG...
|
Healthcare | 1.24% | 1.82% |
#21
4
Prev: #17
|
2.5 | 203,978 | 11.3% |
P
S
|
2,003,978 | $69,558,076 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.17% | 1.42% |
#22
4
Prev: #26
|
1.0 | -493,271 | -18.6% |
P
S
|
2,161,510 | $65,515,368 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 1.10% | 1.74% |
#23
5
Prev: #18
|
0.4 | -389,858 | -32.5% |
P
S
|
810,142 | $61,967,762 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRMD
CORMEDIX INC
|
Healthcare | 1.09% | 0.16% |
#24
22
Prev: #46
|
3.4 | 4,774,076 | 954.8% |
P
S
|
5,274,076 | $61,337,504 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 1.08% | — |
#25
Prev: #—
|
3.9 | 4,610,071 | no change |
NEW
|
4,610,071 | $60,760,736 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.00% | — |
#26
Prev: #—
|
3.9 | 2,000,000 | no change |
NEW
|
2,000,000 | $55,960,000 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 0.92% | 0.71% |
#27
7
Prev: #34
|
2.9 | 650,000 | 32.5% |
P
S
|
2,650,000 | $51,834,000 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.92% | 1.44% |
#28
3
Prev: #25
|
0.9 | -99,262 | -5.0% |
P
S
|
1,900,738 | $51,624,044 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 0.90% | 1.26% |
#29
1
Prev: #28
|
0.9 | -525,325 | -6.7% |
P
S
|
7,334,323 | $50,606,829 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.89% | — |
#30
Prev: #—
|
3.9 | 2,000,000 | no change |
NEW
|
2,000,000 | $50,020,000 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 0.83% | — |
#31
Prev: #—
|
3.8 | 1,000,000 | no change |
NEW
|
1,000,000 | $46,300,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VSTM
VERASTEM INC
|
Healthcare | 0.79% | — |
#32
Prev: #—
|
3.8 | 5,740,850 | no change |
NEW
|
5,740,850 | $44,319,362 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 0.78% | 1.07% |
#33
3
Prev: #30
|
2.3 | 187,347 | 7.7% |
P
S
|
2,614,004 | $43,993,687 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GERN
GERON CORP
|
Healthcare | 0.77% | 1.57% |
#34
15
Prev: #19
|
0.3 | -8,585,251 | -20.9% |
P
S
|
32,511,271 | $42,914,878 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
ENGENE HOLDINGS...
|
Healthcare | 0.70% | 0.43% |
#35
4
Prev: #39
|
3.3 | 2,138,219 | 95.5% |
P
S
|
4,377,572 | $39,529,475 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANIP
ANI PHARMACEUTI...
|
Healthcare | 0.67% | 1.15% |
#36
7
Prev: #29
|
2.3 | 27,684 | 6.2% |
P
S
|
477,684 | $37,708,375 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 0.55% | 1.57% |
#37
17
Prev: #20
|
0.2 | -6,725,952 | -89.7% |
P
S
|
769,048 | $31,069,539 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 0.55% | — |
#38
Prev: #—
|
3.7 | 1,956,867 | no change |
NEW
|
1,956,867 | $30,859,793 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNMD
MIND MEDICINE M...
|
Healthcare | 0.40% | 0.49% |
#39
1
Prev: #38
|
2.2 | 176,540 | 11.8% |
P
S
|
1,676,540 | $22,448,871 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 0.39% | 0.34% |
#40
1
Prev: #41
|
3.2 | 1,000,000 | 68.7% |
P
S
|
2,454,562 | $21,747,419 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 0.36% | 0.11% |
#41
10
Prev: #51
|
3.1 | 3,891,177 | 346.7% |
P
S
|
5,013,661 | $20,054,644 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATAI
ATAI BECKLEY NV
|
Healthcare | 0.34% | — |
#42
Prev: #—
|
3.6 | 4,677,289 | no change |
NEW
|
4,677,289 | $19,130,112 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.29% | 1.34% |
#43
16
Prev: #27
|
0.1 | -833,565 | -69.5% |
P
S
|
366,435 | $16,423,617 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 0.29% | — |
#44
Prev: #—
|
3.6 | 453,102 | no change |
NEW
|
453,102 | $16,094,183 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Healthcare | 0.27% | 0.16% |
#45
Prev: #45
|
3.1 | 854,255 | 85.4% |
P
S
|
1,854,255 | $15,167,806 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.19% | 0.20% |
#46
4
Prev: #42
|
1.1 | no change | no change |
P
S
|
7,419,355 | $10,906,452 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 0.11% | — |
#47
Prev: #—
|
3.5 | 95,408 | no change |
NEW
|
95,408 | $6,230,142 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BHVN
CALL
BIOHAVEN LTD
|
CALL Option | 0.10% | — |
#48
Prev: #—
|
3.5 | 500,000 | no change |
NEW
|
500,000 | $5,645,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.10% | 0.15% |
#49
1
Prev: #48
|
1.0 | no change | no change |
P
S
|
453,686 | $5,380,716 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
ALGS
ALIGOS THERAPEU...
|
Healthcare | 0.07% | 0.12% |
#50
1
Prev: #49
|
1.0 | no change | no change |
P
S
|
444,110 | $4,139,105 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 73 holdings